Jump to content

CF33 is an Oncolytic Virotherapy

Nev Black

Recommended Posts

Imugene is a company listed on the Australian Stock Exchange. (This is not a recommendation to buy shares in this company)

CF33 is an Oncolytic Virotherapy which will be used in a Phase 1 Trial, in Australia, starting next year. CF33 will be trailed on a number of cancers.

Unfortunately, Prostate Cancer was not on the list.  



04/11/2019   Imugene Receives $4.13 million R&D Tax Incentive





21/10/2019   CF33 Oncolytic Virus Clinical Trial Program Update




(The announcements below are publicly available on the Australian Stock Exchange Announcements page)

Link to comment
Share on other sites


  • Create New...